Zymeworks (ZYME) Expected to Announce Earnings on Thursday

Zymeworks (NYSE:ZYME - Get Free Report) is expected to post its quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect Zymeworks to post earnings of ($0.45) per share and revenue of $20.65 million for the quarter.

Zymeworks Stock Up 0.2 %

Shares of ZYME stock traded up $0.03 on Monday, hitting $12.99. The stock had a trading volume of 71,045 shares, compared to its average volume of 609,361. Zymeworks has a one year low of $8.21 and a one year high of $17.70. The business has a 50 day moving average price of $12.01 and a 200 day moving average price of $13.50. The company has a market cap of $903.46 million, a PE ratio of -8.62 and a beta of 1.24.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Lifesci Capital assumed coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price target for the company. HC Wainwright increased their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Finally, Citigroup boosted their price target on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zymeworks has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Insider Buying and Selling

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 73,953 shares of the company's stock in a transaction dated Wednesday, April 16th. The shares were acquired at an average price of $11.16 per share, for a total transaction of $825,315.48. Following the completion of the purchase, the director now owns 17,773,727 shares of the company's stock, valued at approximately $198,354,793.32. The trade was a 0.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have acquired a total of 1,350,347 shares of company stock worth $16,137,499 in the last ninety days. 1.92% of the stock is owned by insiders.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.